Browse by Vaccine Type

This page shows data for Replicating viral vector vaccine type.
Total Entries Retrieved: 26
IDVaccine NameDisease NameDisease ClassificationVirus NameNucleic Acid ContentVaccine TypeVaccine StatusManufacturerYear of ManufacturingManufacturing CountryAgeDosageAdministration RouteAdjuvantTarget StrainDescriptionApproving OrganisationCollaborating OrganisationOther CountriesTrade NamePMIDClinical Trial IDReference LinkAdditional Links
10163 BriLife COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Israel Institute for Biological Research NA NA NA Single dose Intramuscular NA NA NA NA NA NA rVSV-SARS-CoV-2-S Vaccine 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10172 COVID-19 aAPC vaccine COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Shenzhen Geno-Immune Medical Institute 2021 China 6 months - 80 years 3 doses on day 0, 14 and 28 Subcutaneous NA NA The Covid-19/aAPC vaccine is prepared by applying lentivirus modification with immune-modulatory genes and the viral minigenes to the artificial antigen-presenting cells NA NA NA NA 33816047 NCT04299724 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA
10189 TMV-083 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Institut Pasteur 2020 Belgium 18 - 55 years 2 doses 28 days apart Intramuscular NA Surface glycoprotein of the SARS-CoV-2 NA NA NA NA MV-SARS-CoV-2 NA NCT04497298 https://clinicaltrials.gov/show/NCT04497298 NA
10191 V590-001 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 1 Merck & Co. Inc. 2020 USA 18 years and above NA Intramuscular NA NA NA US FDA NA NA NA NA NCT04569786 https://clinicaltrials.gov/show/NCT04569786 NA
10264 DelNS1-2019-nCoV-RBD-OPT1 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 2 Beijing Wantai Biological NA NA NA Single dose Intranasal NA NA NA NA Jiangsu Province Centers for Disease Control and Prevention NA NA 33816047 NCT04809389 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ https://clinicaltrials.gov/ct2/show/NCT04809389
10265 TMV-o38 COVID-19 Respiratory SARS-CoV-2 virus positive-sense, single-stranded RNA Replicating viral vector Phase 2 Merck & Co. Inc. NA NA NA 2 doses 28 days apart Intramuscular NA NA NA NA Themis, Sharp & Dohme, Institute Pasteur, Univeristy of Pittsburgh NA V591-001—Measles-vector based 33816047 NA https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ NA